ABBISKO CAYMAN DL-00001
Abbisko Cayman Limited engages in the research and development of pharmaceutical products in the People's Republic of China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor in NDA/commercial trial for the treatment of tenosynovial giant cell tumors, as well as chronic graft versus host disease and solid tumors. It is also developing pivotal tri… Read more
ABBISKO CAYMAN DL-00001 (8ZD) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ABBISKO CAYMAN DL-00001 (8ZD) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ABBISKO CAYMAN DL-00001 - Net Assets Trend (None–None)
This chart illustrates how ABBISKO CAYMAN DL-00001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ABBISKO CAYMAN DL-00001 (None–None)
The table below shows the annual net assets of ABBISKO CAYMAN DL-00001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ABBISKO CAYMAN DL-00001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ABBISKO CAYMAN DL-00001 Competitors by Market Cap
The table below lists competitors of ABBISKO CAYMAN DL-00001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ZKH Group Limited
NYSE:ZKH
|
$592.31 Million |
|
VGI Public Company Limited
BK:VGI-R
|
$592.33 Million |
|
Asiainfo Security Technologies Corp. A
SHG:688225
|
$592.37 Million |
|
Inno Laser Technology Co. Ltd.
SHE:301021
|
$592.42 Million |
|
Cablevisión Holding S.A
PINK:CVHSY
|
$592.21 Million |
|
Ngern Tid Lor Public Company Limited
BK:TIDLOR
|
$592.18 Million |
|
Solid Power Inc
NASDAQ:SLDP
|
$592.17 Million |
|
POLAR CAP.HLDGS LS -025
F:XZF
|
$592.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ABBISKO CAYMAN DL-00001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ABBISKO CAYMAN DL-00001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ABBISKO CAYMAN DL-00001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ABBISKO CAYMAN DL-00001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ABBISKO CAYMAN DL-00001 (8ZD) | €- | N/A | N/A | $592.27 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |